The extended cash runway through 2027 reduces near-term dilution risk. Upcoming catalysts include AACR data in April 2026, IND submission for XTX501 mid-2026, and potential Series C warrant exercises ($36.2M possible). Monitor progress on clinical milestones and partnership developments with AbbVie and Gilead.
Price Chart
Executive Summary
Xilio Therapeutics reported strong financial results for Q4 and full year 2025, driven by a $17.5M milestone from Gilead and $35.8M in warrant exercises, boosting cash to $137.5M and extending its runway to end of 2027. The company advanced its pipeline, including progress on XTX501 (IND mid-2026) and two first-in-class masked T cell engager programs. Despite a reduced annual net loss, it remains pre-revenue with no product sales.
Key Financial Metrics
Key Facts
- Cash and cash equivalents increased to $137.5M as of December 31, 2025, up from $55.3M in 2024
- Collaboration and license revenue surged to $43.8M in 2025 (from $6.3M in 2024), primarily due to AbbVie and Gilead agreements
- Net loss narrowed to $35.0M in 2025 from $58.2M in 2024
- XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 initiation in second half of 2026
- Advancing first-in-class multi-specific masked T cell engager targeting PSMA/STEAP1 for prostate cancer
- New preclinical data for CLDN18.2 program to be presented at AACR in April 2026
- Raised $40.0M in gross proceeds from prefunded warrant offering in February 2026
Financial Impact
Cash position increased by $82.2M YoY to $137.5M; collaboration revenue up 594% YoY to $43.8M; annual net loss reduced by 39.9% to $35.0M
Risk Factors
- High R&D spend ($56.0M in 2025) with no near-term revenue potential
- Heavy reliance on partnership funding and future warrant exercises
- Clinical-stage biotech with unproven pipeline; preclinical data may not translate to human efficacy
- Dilution risk if Series C warrants are exercised or future offerings are needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260273 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.16 (−9.81%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.16 (+1.06%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.16 (−4.20%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.16 (+5.60%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.16 (−3.40%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.16 (−4.75%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.16 (−2.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers